Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Seegene, Inc.
  6. News
  7. Summary
    A096530   KR7096530001

SEEGENE, INC.

(A096530)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Seegene to Supply Covid-19 Diagnostic Tests Worth GBP 16 Million to Scotland

04/21/2021 | 09:27pm EDT

Seegene Inc. said it began supplying its COVID-19 diagnostic tests worth 16,209,150 GBP to Scotland under a public procurement agreement, the largest diagnostic volume seen in that region since the pandemic. Compared to Seegene's annual sales tallied in Scotland, the supply contract is worth triple the volume in 2020, which came in at GBP 5,400,000 .Under the supplying deal, Seegene'sScotland dealership, Mast Group, will be supplying Allplex™ SARS CoV-2 to the National Health Care Scotland NSS, which will then be distributed to 9 hospitals including Royal Infirmary Edinburgh and Ninewell starting in April. Seegene's COVID-19 diagnostic test, the Allplex™ SARS CoV-2 Assay is a unique multiplex real-time PCR assay that can detect a total of five targets including four coronavirus genes (E gene, RdRp gene, N gene and S gene) and an exogenous control (entire process control) in a single reaction tube, allowing accurate results and maximize throughput for high volume testing. The diagnostic test previously acquired CE-IVD mark in June 2020. Seegene recently began exporting both Allplex™ SARS-CoV-2 Master Assay and Allplex™ SARS-CoV-2 Variants l Assay to over 20 countries around the world, including the hardest hit European countries including the UK, Italy, Germany as well as Chile after having acquired CE-IVD mark in March. Seegene's exceptional technological skills are being recognized once again through a series of public procurement agreements including the most recent tender deal secured in Italy via its subsidiary office, worth over EUR 89.3 million. Yi said Seegene hopes to realize additional market expansion soon through its aggressive marketing strategies elsewhere around the world.


ę S&P Capital IQ 2021
All news about SEEGENE, INC.
09/01SEEGENE : Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four C..
AQ
08/18SEEGENE : Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY
AQ
08/18Seegene Inc. Reports Earnings Results for the Second Quarter and First Half Ended June ..
CI
07/13SEEGENE : Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Vari..
AQ
07/13Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Var..
CI
07/06SEEGENE : announces partnership with Bio-Rad to develop diagnostic testing products for th..
AQ
07/02Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on March 9, 2021.
CI
07/02Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on March 9, 2021.
CI
06/29SEEGENE : unveils "MOBILE STATION," for on-site routine testing at public-use facilities a..
AQ
06/29Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at th..
CI
More news
Financials
Sales 2021 1 244 B 1,05 B 1,05 B
Net income 2021 486 B 0,41 B 0,41 B
Net Debt 2021 - - -
P/E ratio 2021 7,11x
Yield 2021 5,67%
Capitalization 3 429 B 2 903 M 2 908 M
Capi. / Sales 2021 2,76x
Capi. / Sales 2022 4,80x
Nbr of Employees 833
Free-Float 67,9%
Chart SEEGENE, INC.
Duration : Period :
Seegene, Inc. Technical Analysis Chart | A096530 | KR7096530001 | MarketScreener
Technical analysis trends SEEGENE, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 66 200,00 KRW
Average target price 89 000,00 KRW
Spread / Average Target 34,4%
EPS Revisions
Managers and Directors
Jong-Yoon Chun Chief Executive Officer & Director
Jung-Yong Kim Director & Head-Finance
Hong-Il Yoon Independent Director
Chang-Se Lee Independent Director
Kyung-Jun Chun Director
Sector and Competitors
1st jan.Capi. (M$)
SEEGENE, INC.-31.40%2 903
EXACT SCIENCES CORPORATION-25.87%16 511
GUARDANT HEALTH, INC.-0.37%13 007
INVITAE CORPORATION-28.10%6 533
BGI GENOMICS CO., LTD.-28.50%5 827
ADAPTIVE BIOTECHNOLOGIES CORPORATION-38.29%5 137